Interaction among cells of bone, immune system, and solid tumors leads to bone metastases

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Roato, Ilaria ^a  

^a CERMS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; CYTOKINE; DENOSUMAB; DKK 1 ANTIBODY; ET 1 ANTIBODY; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN SRC INHIBITOR; UNCLASSIFIED DRUG; TUMOR PROTEIN;

BONE; BONE CELL; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; LUNG CANCER; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; CELL COMMUNICATION; FEMALE; GENETICS; IMMUNOLOGY; KIDNEY TUMOR; LUNG TUMOR; MALE; METABOLISM; OSTEOBLAST; OSTEOCLAST; PATHOLOGY; PROSTATE TUMOR; SECONDARY; METASTASIS;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL COMMUNICATION; CYTOKINES; FEMALE; HUMANS; IMMUNE SYSTEM; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 84877975744     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/315024     Document Type: Review

References (78)

1. Coleman R. E., Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research 2006 12 20, part 2 6243s 6249s 10.1158/1078-0432.CCR-06-0931 (Pubitemid 44703797)
2. Coleman R. E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews 2001 27 3 165 176 2-s2.0-0035010803 10.1053/ctrv.2000.0210 (Pubitemid 32452017)
3. Roodman G. D., Mechanisms of bone metastasis. The New England Journal of Medicine 2004 350 16 1655 1664 2-s2.0-4644261592 10.1056/NEJMra030831 (Pubitemid 38501167)
4. Teitelbaum S. L., Bone resorption by osteoclasts. Science 2000 289 5484 1504 1508 2-s2.0-0034284970 10.1126/science.289.5484.1504
5. Roodman G. D., Cell biology of the osteoclast. Experimental Hematology 1999 27 8 1229 1241 2-s2.0-0032765892 10.1016/S0301-472X(99)00061-2 (Pubitemid 29347472)
6. Logothetis C. J., Lin S. H., Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer 2005 5 1 21 28 2-s2.0-11144237716 10.1038/nrc1528 (Pubitemid 40052322)
7. Takayanagi H., New developments in osteoimmunology. Nature Reviews Rheumatology 2012 8 11 684 689 10.1038/nrrheum.2012.167
8. Kasagi S., Chen W., TGF-beta1 on osteoimmunology and the bone component cells. Cell & Bioscience 2013 3 1, article 4 10.1186/2045-3701-3-4
9. Kostenuik P. J., Shalhoub V., Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Current Pharmaceutical Design 2001 7 8 613 635 2-s2.0-0035024957 10.2174/1381612013397807 (Pubitemid 32427765)
10. Hofbauer L. C., Kühne C. A., Viereck V., The OPG/RANKL/RANK system in metabolic bone diseases. Journal of Musculoskeletal Neuronal Interactions 2004 4 3 268 275 2-s2.0-8644276338 (Pubitemid 39504354)
11. Santini D., Perrone G., Roato I., Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. Journal of Cellular Physiology 2011 226 3 780 784 10.1002/jcp.22402
12. Hofbauer L. C., Khosla S., Dunstan C. R., Lacey D. L., Boyle W. J., Riggs B. L., The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 2000 15 1 2 12 2-s2.0-0033984313 (Pubitemid 30026926)
13. Pacifici R., The immune system and bone. Archives of Biochemistry and Biophysics 2010 503 1 41 53 2-s2.0-77956744791 10.1016/j.abb.2010.05.027
14. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K., Nakamura K., Taniguchi T., T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN- γ Nature 2000 408 6812 600 605 2-s2.0-0034735773 10.1038/35046102
15. Sato K., Satoh T., Shizume K., Yamakawa Y., Ono Y., Demura H., Akatsu T., Takahashi N., Suda T., Prolonged decrease of serum calcium concentration by murine γ -interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. Cancer Research 1992 52 2 444 449 2-s2.0-0026512412
16. Gao Y., Grassi F., Ryan M. R., Terauchi M., Page K., Yang X., Weitzmann M. N., Pacifici R., IFN- γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. Journal of Clinical Investigation 2007 117 1 122 132 2-s2.0-33845981069 10.1172/JCI30074 (Pubitemid 46048459)
17. Cenci S., Toraldo G., Weitzmann M. N., Roggia C., Gao Y., Qian W. P., Sierra O., Pacifici R., Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN- γ -induced class II transactivator. Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10405 10410 2-s2.0-0041836267 10.1073/pnas. 1533207100 (Pubitemid 37071891)
18. Abbas S., Abu-Amer Y., Dominant-negative I B facilitates apoptosis of osteoclasts by tumor necrosis factor- α Journal of Biological Chemistry 2003 278 22 20077 20082 2-s2.0-0038504087 10.1074/jbc.M208619200 (Pubitemid 36799201)
19. Pacifici R., Estrogen deficiency, T cells and bone loss. Cellular Immunology 2008 252 1-2 68 80 2-s2.0-48149084609 10.1016/j.cellimm.2007.06.008
20. Namen A. E., Lupton S., Hjerrild K., Wignall J., Mochizuki D. Y., Schmierer A., Mosley B., March C. J., Urdal D., Gillis S., Cosman D., Goodwin R. G., Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988 333 6173 571 573 2-s2.0-0024282606
21. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., Suda T., Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proceedings of the National Academy of Sciences of the United States of America 1997 94 17 9360 9365 2-s2.0-0030875168 10.1073/pnas.94.17.9360 (Pubitemid 27357834)
22. Weitzmann M. N., Roggia C., Toraldo G., Weitzmann L., Pacifici R., Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. Journal of Clinical Investigation 2002 110 11 1643 1650 2-s2.0-0036897349 10.1172/JCI200215687 (Pubitemid 35424242)
23. Toraldo G., Roggia C., Qian W. P., Pacific R., Weitzmann M. N., IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor B ligand and tumor necrosis factor α from T cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 1 125 130 2-s2.0-0037422560 10.1073/pnas.0136772100 (Pubitemid 36078040)
24. Giuliani N., Colla S., Sala R., Moroni M., Lazzaretti M., La Monica S., Bonomini S., Hojden M., Sammarelli G., Barillè S., Bataille R., Rizzoli V., Human myeloma cells stimulate the receptor activator of nuclear factor- B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002 100 13 4615 4621 2-s2.0-0037114636 10.1182/blood-2002-04- 1121 (Pubitemid 35429706)
25. Roato I., Brunetti G., Gorassini E., Grano M., Colucci S., Bonello L., Buffoni L., Manfredi R., Ruffini E., Ottaviani D., Ciuffreda L., Mussa A., Ferracini R., IL-7 up-regulates TNF- α -dependent osteoclastogenesis in patients affected by solid tumor. PLoS One 2006 1 1, article e124 2-s2.0-35448982256 10.1371/journal.pone.0000124
26. D'Amelio P., Grimaldi A., Di Bella S., Brianza S. Z. M., Cristofaro M. A., Tamone C., Giribaldi G., Ulliers D., Pescarmona G. P., Isaia G., Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 2008 43 1 92 100 2-s2.0-44949083462 10.1016/j.bone.2008.02.017
27. + T cells. Journal of Immunology 2009 182 9 5477 5487 2-s2.0-66949172165 10.4049/jimmunol.0803897
28. Senthilkumar R., Lee H. W., CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation. Immunobiology 2009 214 2 153 161 2-s2.0-58349112745 10.1016/j.imbio.2008.05.001
29. Paget S., The distribution of secondary growths in cancer of the breast. The Lancet 1889 133 3421 571 573 2-s2.0-50549121134
30. Salcedo R., Oppenheim J. J., Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003 10 3-4 359 370 2-s2.0-0142172456 10.1038/sj.mn.7800200 (Pubitemid 39004262)
31. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K. J., Mehra R., Loberg R., Taichman R. S., The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry 2008 283 7 4283 4294 2-s2.0-42949133032 10.1074/jbc.M707465200
32. Hauschka P. V., Mavrakos A. E., Iafrati M. D., Doleman S. E., Klagsbrun M., Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. Journal of Biological Chemistry 1986 261 27 12665 12674 2-s2.0-0023037767 (Pubitemid 17204223)
33. Sethi N., Dai X., Winter C. G., Kang Y., Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011 19 2 192 205 2-s2.0-79751472667 10.1016/j.ccr.2010.12. 022
34. Santagata S., Demichelis F., Riva A., Varambally S., Hofer M. D., Kutok J. L., Kim R., Tang J., Montie J. E., Chinnaiyan A. M., Rubin M. A., Aster J. C., JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 2004 64 19 6854 6857 2-s2.0-4944241544 10.1158/0008-5472.CAN-04-2500 (Pubitemid 39330990)
35. Chiba S., Notch signaling in stem cell systems. Stem Cells 2006 24 11 2437 2447 2-s2.0-33750566665 10.1634/stemcells.2005-0661 (Pubitemid 44674304)
36. Bellahcene A., Merville M. P., Castronovo V., Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Research 1994 54 11 2823 2826 2-s2.0-0028242627 (Pubitemid 24187753)
37. Bellahcene A., Castronovo V., Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology 1995 146 1 95 100 2-s2.0-0028816321
38. Koeneman K. S., Yeung F., Chung L. W., Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999 39 4 246 261 (Pubitemid 29244499)
39. Lin D. L., Tarnowski C. P., Zhang J., Dai J., Rohn E., Patel A. H., Morris M. D., Keller E. T., Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001 47 3 212 221 2-s2.0-0035873861 10.1002/pros.1065 (Pubitemid 32378373)
40. Cox R. F., Jenkinson A., Pohl K., Osteomimicry of mammary adenocarcinoma cells in vitro, increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One 2012 7 7 e41679
41. + T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research 2011 71 14 4799 4808 2-s2.0-79960414809 10.1158/0008-5472.CAN-10-3922
42. Miossec P., Korn T., Kuchroo V. K., Interleukin-17 and type 17 helper T cells. The New England Journal of Medicine 2009 361 9 848 898 2-s2.0-69349093225 10.1056/NEJMra0707449
43. Feuerer M., Rocha M., Bai L., Umansky V., Solomayer E. F., Bastert G., Diel I. J., Schirrmacher V., Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. International Journal of Cancer 2001 92 1 96 105 2-s2.0-0035314014 (Pubitemid 32187038)
44. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J. Q., Hoffman R. M., Karin M., Tumour-infiltrating regulatory T cells stimulate mammary cancermetastasis through RANKL-RANK signalling. Nature 2011 470 7335 548 553 2-s2.0-79952193038 10.1038/nature09707
45. Wrzesinski S. H., Wan Y. Y., Flavell R. A., Transforming growth factor- β and the immune response: implications for anticancer therapy. Clinical Cancer Research 2007 13 18, part 1 5262 5270 2-s2.0-34848857434 10.1158/1078-0432.CCR-07-1157 (Pubitemid 47510349)
46. Schilbach K., Geiselhart A., Handgretinger R., Induction of proliferation and augmented cytotoxicity of γ δ T lymphocytes by bisphosphonate clodronate. Blood 2001 97 9 2917 2918 2-s2.0-0035353168 10.1182/blood.V97.9.2917
47. 2+ signaling. FEBS Letters 2009 583 7 1164 1170 2-s2.0-63149187085 10.1016/j.febslet.2009.03.005
48. Roato I., Grano M., Brunetti G., Colucci S., Mussa A., Bertetto O., Ferracini R., Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal 2005 19 2 228 230 2-s2.0-13244273716 10.1096/fj.04-1823fje (Pubitemid 40189264)
49. Cenci S., Weitzmann M. N., Roggia C., Namba N., Novack D., Woodring J., Pacifici R., Estrogen deficiency induces bone loss by enhancing T-cell production of TNF- α Journal of Clinical Investigation 2000 106 10 1229 1237 2-s2.0-0033708837
50. Ryan M. R., Shepherd R., Leavey J. K., Gao Y., Grassi F., Schnell F. J., Qian W. P., Kersh G. J., Weitzmann M. N., Pacifici R., An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proceedings of the National Academy of Sciences of the United States of America 2005 102 46 16735 16740 2-s2.0-28044466907 10.1073/pnas.0505168102 (Pubitemid 41688846)
51. Roato I., D'Amelio P., Gorassini E., Grimaldi A., Bonello L., Fiori C., Delsedime L., Tizzani A., De Libero A., Isaia G., Ferracini R., Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008 3 11 2-s2.0-56149084790 10.1371/journal.pone.0003627 e3627
52. Roato I., Gorassini E., Buffoni L., Lyberis P., Ruffini E., Bonello L., Baldi I., Ciuffreda L., Mussa A., Ferracini R., Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer. Lung Cancer 2008 61 1 109 116 2-s2.0-45649085772 10.1016/j.lungcan.2007.10.016
53. Roato I., Caldo D., Godio L., D'Amico L., Giannoni P., Morello E., Quarto R., Molfetta L., Buracco P., Mussa A., Ferracini R., Bone invading NSCLC cells produce IL-7: mice model and human histologic data. BMC Cancer 2010 10 article 12 2-s2.0-77349088312 10.1186/1471-2407-10-12
54. Keller E. T., Zhang J., Cooper C. R., Smith P. C., McCauley L. K., Pienta K. J., Taichman R. S., Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews 2001 20 3-4 333 349 2-s2.0-0035740253 10.1023/A:1015599831232 (Pubitemid 34595275)
55. Hall C. L., Kang S., MacDougald O. A., Keller E. T., Role of Wnts in prostate cancer bone metastases. Journal of Cellular Biochemistry 2006 97 4 661 672 2-s2.0-33645006198 10.1002/jcb.20735
56. Clines G. A., Mohammad K. S., Bao Y., Stephens O. W., Suva L. J., Shaughnessy J. D., Fox J. W., Chirgwin J. M., Guise T. A., Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology 2007 21 2 486 498 2-s2.0-33846624243 10.1210/me.2006-0346 (Pubitemid 46184897)
57. Zhang J., Dai J., Qi Y., Lin D. L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., Keller E. T., Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. Journal of Clinical Investigation 2001 107 10 1235 1244 2-s2.0-0035021176 (Pubitemid 32494540)
58. Morony S., Capparelli C., Sarosi I., Lacey D. L., Dunstan C. R., Kostenuik P. J., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Research 2001 61 11 4432 4436 2-s2.0-0035360265 (Pubitemid 32685771)
59. Lipton A., Steger G. G., Figueroa J., Alvarado C., Solal-Celigny P., Body J. J., De Boer R., Berardi R., Gascon P., Tonkin K. S., Coleman R., Paterson A. H. G., Peterson M. C., Fan M., Kinsey A., Jun S., Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Journal of Clinical Oncology 2007 25 28 4431 4437 2-s2.0-35348897212 10.1200/JCO.2007.11.8604 (Pubitemid 350013849)
60. Body J. J., Facon T., Coleman R. E., Lipton A., Geurs F., Fan M., Holloway D., Peterson M. C., Bekker P. J., A study of the biological receptor activator of nuclear factor- ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical Cancer Research 2006 12 4 1221 1228 2-s2.0-33644760436 10.1158/1078-0432.CCR-05-1933 (Pubitemid 43342512)
61. Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W. C., Baron R., Src kinase activity is essential for osteoclast function. Journal of Biological Chemistry 2004 279 17 17660 17666 2-s2.0-2342442847 10.1074/jbc.M311032200 (Pubitemid 38560531)
62. Soriano P., Montgomery C., Geske R., Bradley A., Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991 64 4 693 702 2-s2.0-0026023289 (Pubitemid 121001157)
63. Zaidi S. K., Sullivan A. J., Medina R., Ito Y., Van Wijnen A. J., Stein J. L., Lian J. B., Stein G. S., Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO Journal 2004 23 4 790 799 2-s2.0-1842457741 10.1038/sj.emboj.7600073 (Pubitemid 38418746)
64. Frame M. C., Src in cancer: deregulation and consequences for cell behaviour. Biochimica et Biophysica Acta 2002 1602 2 114 130 2-s2.0-0037150728 10.1016/S0304-419X(02)00040-9 (Pubitemid 34521791)
65. Hannon R. A., Clack G., Rimmer M., Swaisland A., Andrew Lockton J., Finkelman R. D., Eastell R., Effects of the Src kinase inhibitor saracatinib (azd0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. Journal of Bone and Mineral Research 2010 25 3 463 471 2-s2.0-77953433829 10.1359/jbmr.090830
66. Gucalp A., Sparano J. A., Caravelli J., Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clinical Breast Cancer 2011 11 5 306 311 10.1016/j.clbc.2011.03.021
67. Brubaker K. D., Vessella R. L., True L. D., Thomas R., Corey E., Cathepsin K mRNA and protein expression in prostate cancer progression. Journal of Bone and Mineral Research 2003 18 2 222 230 2-s2.0-0037302046 10.1359/jbmr.2003.18.2.222 (Pubitemid 36125914)
68. Littlewood-Evans A. J., Bilbe G., Bowler W. B., Farley D., Wlodarski B., Kokubo T., Inaoka T., Sloane J., Evans D. B., Gallagher J. A., The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Research 1997 57 23 5386 5390 2-s2.0-15144356711 (Pubitemid 27516378)
69. Le Gall C., Bellahcène A., Bonnelye E., Gasser J. A., Castronovo V., Green J., Zimmermann J., Clézardin P., A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden. Cancer Research 2007 67 20 9894 9902 2-s2.0-35448959223 10.1158/0008-5472.CAN-06-3940 (Pubitemid 47621238)
70. Jensen A. B., Wynne C., Ramirez G., He W., Song Y., Berd Y., Wang H., Mehta A., Lombardi A., The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical Breast Cancer 2010 10 6 452 458 2-s2.0-79952278967
71. Leto G., Incorvaia L., Badalamenti G., Tumminello F. M., Gebbia N., Flandina C., Crescimanno M., Rini G., Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clinical and Experimental Metastasis 2006 23 2 117 122 2-s2.0-33748954261 10.1007/s10585-006-9010-5 (Pubitemid 44440171)
72. Chantry A. D., Heath D., Mulivor A. W., Pearsall S., Baud'Huin M., Coulton L., Evans H., Abdul N., Werner E. D., Bouxsein M. L., Key M. L., Seehra J., Arnett T. R., Vanderkerken K., Croucher P., Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research 2010 25 12 2357 2370 2-s2.0-77957727888 10.1002/jbmr.142
73. Vallet S., Mukherjee S., Vaghela N., Hideshima T., Fulciniti M., Pozzi S., Santo L., Cirstea D., Patel K., Sohani A. R., Guimaraes A., Xie W., Chauhan D., Schoonmaker J. A., Attar E., Churchill M., Weller E., Munshi N., Seehra J. S., Weissleder R., Anderson K. C., Scadden D. T., Raje N., Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences of the United States of America 2010 107 11 5124 5129 2-s2.0-77950438331 10.1073/pnas.0911929107
74. Spencer G. J., Utting J. C., Etheridge S. L., Arnett T. R., Genever P. G., Wnt signalling in osteoblasts regulates expression of the receptor activator of NF B ligand and inhibits osteoclastogenesis in vitro. Journal of Cell Science 2006 119 7 1283 1296 2-s2.0-33646808104 10.1242/jcs.02883
75. Heath D. J., Chantry A. D., Buckle C. H., Coulton L., Shaughnessy J. D., Evans H. R., Snowden J. A., Stover D. R., Vanderkerken K., Croucher P. I., Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research 2009 24 3 425 436 2-s2.0-61849137831 10.1359/jbmr.081104
76. Qiao L., Xu Z. L., Zhao T. J., Ye L. H., Zhang X. D., Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Letters 2008 269 1 67 77 2-s2.0-49349100584 10.1016/j.canlet.2008.04.032
77. Chiao J. W., Moonga B. S., Yang Y. M., Kancherla R., Mittelman A., Wu-Wong J. R., Ahmed T., Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer 2000 83 3 360 365 2-s2.0-0033919232 (Pubitemid 30453577)
78. Yin J. J., Mohammad K. S., Kakonen S. M., A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America 2003 100 19 10954 10959 10.1073/pnas.1830978100 (Pubitemid 37140134)